Partner for Pembrolizumab Combination After Prostate Cancer ∙∙∙

Cellbion Participates in BIO Europe Fall: Showcases Its Pros∙∙∙

K-Radiation Oncology Cellbion Sets Stage for Rebound With Fa∙∙∙

Misconceptions About Data Fluctuation Due to Patient Numbers∙∙∙

Cellbion Signs Joint Research Agreement with Zymedi for “Ant∙∙∙

Cellbion CEO Kim Kwon Confronts Clinical Trial Controversy: ∙∙∙

Cellbion: “New prostate cancer drug to launch next year”∙∙∙

Cellbion’s Keytruda combination trial, strategy to overtake ∙∙∙

Cellbion receives MFDS IND approval for Phase 1 clinical tri∙∙∙

Cellbion's successful Phase 2 clinical trial for prostate ca∙∙∙

Next-generation cancer drug 'radiopharmaceuticals' on the ri∙∙∙

Kim Kwon, CEO of Cellbion, said, "Combined clinical trial wi∙∙∙

Kim Kwon, CEO of Cellbion, said, "Challenge for a new drug f∙∙∙

Cellbion Emerges as a Dark Horse in Radiopharmaceuticals∙∙∙

[BIO USA] CellBion to announce topline Phase 2 clinical tria∙∙∙

Cellbion, MSD Keytruda apply for phase 1 clinical trial in K∙∙∙

Cellbion, the second half of its fate, enters a combined cli∙∙∙

Cellbion, Merck set to launch clinical trials... Aiming for ∙∙∙

Cellbion Moves Toward Potential Commercial Launch of Prostat∙∙∙

Cellbion Expands Combination Clinical Trial Targeting in Par∙∙∙